Evidence map›Paper›PMID 29940912›Full record

ArticleBMC cancer2018

Heparan sulfate proteoglycans undergo differential expression alterations in left sided colorectal cancer, depending on their metastatic character.

Ainara Crespo, Olivia García-Suárez, Iván Fernández-Vega, María Pilar Solis-Hernandez, Beatriz García, Sonia Castañón, Luis M Quirós

Abstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment.International journal of molecular sciences · 2020
    Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ainara CrespoDepartment of Biotechnology, Neiker-Tecnalia Arkaute, 01080, Vitoria-Gasteiz, Spain.
Olivia García-SuárezInstituto Universitario Fernández-Vega, and Department of Morphology and Cell Biology, University of Oviedo, 33006, Oviedo, Spain.
Iván Fernández-VegaInstituto Universitario Fernández-Vega, and Department of Pathology, Hospital Universitario Central de Asturias, Oviedo, 33006, Spain.
María Pilar Solis-HernandezDepartment of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Beatriz GarcíaInstituto Universitario Fernández-Vega, and Department of Functional Biology, University of Oviedo, 33006, Oviedo, Spain.
Sonia CastañónDepartment of Biotechnology, Neiker-Tecnalia Arkaute, 01080, Vitoria-Gasteiz, Spain.
Luis M QuirósInstituto Universitario Fernández-Vega, and Department of Functional Biology, University of Oviedo, 33006, Oviedo, Spain. quirosluis@uniovi.es.ORCID http://orcid.org/0000-0003-3505-3762

Funding

Gobierno del Principado de Asturias FC-15-GRUPIN14-141Instituto de Salud Carlos III PI051564
6 · The paper itself

Abstract

backgroundHeparan sulfate proteoglycans (HSPGs) are complex molecules which play a role in the invasion and growth and metastatic properties of cancerous cells. In this work we analyze changes in the patterns of expression of HSPGs in left sided colorectal cancer (LSCRC), both metastatic and non-metastatic, and the results are also compared with those previously obtained for right sided tumors (RSCRCs).

methodsEighteen LSCRCs were studied using qPCR to analyze the expression of both the proteoglycan core proteins and the enzymes involved in heparan sulfate chain biosynthesis. Certain HSPGs also carry chondroitin sulfate chains and so we also studied the genes involved in its biosynthesis. The expression of certain genes that showed significant expression differences were also analysed using immunohistochemical techniques.

resultsChanges in proteoglycan core proteins were dependent on their location, and the main differences between metastatic and non-metastatic tumors affected cell-surface glypicans, while other molecules were quite similar. Glypicans were also responsible for the main differences between RS- and LS- malignances. Regarding the biosynthesis of heparan sulfate chains, differential alterations in transcription depending on the presence or not of metastasis affected genes involved in the modification of uronic acid (epimerization and 2-O sulfation), and some isoforms responsible for sulfation of glucosamine (NDST1, HS6ST1). Moreover, in RSCRCs differences were preferentially found in the expression of genes involved in C6 and C3 sulfation of glucosamine, but not in NDSTs or SULFs. Finally, synthesis of chondroitin sulfate showed some alterations, which affected various steps, including polimerization and the modification of chains, but the main variations dependent on the presence of metastases were epimerization and 6C sulfation; however, when compared with RSCRCs, the essential divergences affected polymerization of the chains and the 6C sulfation of the galactosamine residue.

conclusionsWe evidenced alterations in the expression of HSPGs, including the expression of cell surface core proteins, many glycosiltransferases and some enzymes that modify the GAG chains in LSCRCs, but this was dependent on the metastatic nature of the tumor. Some of these alterations are shared with RSCRCs, while others, focused on specific gene groups, are dependent on tumor localization.

Indexed as

AgedAged, 80 and overColorectal NeoplasmsFemaleGlycosyltransferasesHeparan Sulfate ProteoglycansHumansImmunohistochemistryMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingGlycosyltransferasesHeparan Sulfate ProteoglycansChondroitin sulfateColorectal cancerGlycosaminoglycanHeparan sulfateProteoglycan

Identifiers

PMID29940912
PMCPMC6019305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.